Stats

Start49.14Catalystcash,850.99account,flat; goal repeatable net pre-event gains; binding constraint independently validated executable edge. Premises: (1) queried ledger has all3closed, no pending/open; own20armedmonitors none due by nextSep7 00UTCrun. (2) Rechecked primary https://www.nyse.com/trade/hours-calendars listsSep7holiday and Aug19 issuer https://investor.chewy.com/news-and-events/news/news-details/2026/Chewy-Announces-Fiscal-Second-Quarter-Financial-Results-Conference-Call/default.aspx confirmsSep9before-open,08ETcall; onlyone regularsession remains. (3) queried saved vectorbt backtest38: preregistered12train/6holdout,5bpfee+5bpslippage eachside,holdout-1.719988%,DD14.258614%,p50%,W4.523391%,L4.828695%,95%meanCI[-4.527052,3.687206]%; Python expectancy-.152652% per9-session exposure, clippedquarterKelly0. (4) saved technical435 R/R1.0337<1.5, Fridayreferences are not fresh quotes; no one-session replacement validated. Conclusion no proposals. Validity: required entry conjunction fails. Soundness: small selected historical sample, IEX execution and revised calendars limit transfer; no new test or exhaustive primary sweep claimed. Counterexample favorable future report/rally could reward an untested entry, but cannot establish its ex-ante edge. Evidence to change size: independently preregistered comparable net holdout with supported positive expectancy plus fresh executable levels and pre-first-news exit; a date alone changes watch only. Beneficiary of cash is future book optionality; operator349.01shortfall does not change probability. Consequence chain of unvalidated holiday limit: possible pre-news fill -> adverse binary gap bypasses stop -> smaller future book. Cash avoids that exposure but forgoes possible upside. Saved jobs30/33 containEND; job33 twice still lastRun12:30,nextRun16:30 at16:32UTC, so currentdelivery unverified. No overdue own event/exposure makes duplicate collector necessary; retain active jobs and handoff freshness check. Job9 remains truncated headline discovery, not primary assurance. Existing monitors keep favorable->record/validate and adverse/delayed->cash branches. OtherfundFIVE overdue monitor belongs CIO, not Catalyst.

Start: Catalyst49.14cash,account850.99,flat; goal repeatable net pre-event gains; binding constraint validated executable edge. Premise1 live fund ledger has no open or pending orders and20armed monitors none due before nextSep7 00UTCrun. Premise2 NYSE https://www.nyse.com/trade/hours-calendars confirmsSep7holiday; CHWY Aug19 issuer https://investor.chewy.com/news-and-events/news/news-details/2026/Chewy-Announces-Fiscal-Second-Quarter-Financial-Results-Conference-Call/default.aspx rechecked confirmsSep9beforeopen,08ETcall, leavingone regularsession. Premise3 saved preregistered vectorbt backtest38 had12training/6holdout,20bpapproxroundtrip costs,holdout-1.719988%,DD14.258614%,50%wins,W4.523391%,L4.828695%,mean-.152652%,bootstrap95%mean[-4.527052,3.687206]%; quarterKelly0. Positive CLI baseline58 is no-cost/full-window and not this event rule. Premise4 saved technical435 R/R1.0337<1.5; no fresh quote or one-session validation exists. Conclusion no proposal,exit,adjustment or newfund. Validity: required eligibility conjunction fails. Soundness limits: N6 selected issuer/historical holdout, stale Friday references and imperfect execution model; not proof all runups fail. Strong countercase favorable earnings or higher price could occur, but neither supplies known net pre-event odds. Who benefits: preserving cash retains future optionality; no operator shortfall used in allocation. Consequences: queued holiday exposure could fill before news -> binary gap can bypass stop -> diminished future book; avoiding that exposure costs possible gains but respects unvalidated edge. Monitoring: list_jobs confirms30END1189chars and33END1552chars,exit0; prior first-sandbox uncertainty441 resolved. Latest-only RSS/SEC is bounded coverage;9 remains2000char truncated discovery. No newcollector,monitor or backtest warranted for unchanged rejected setup. Existing conditional positive->record/validate;negative/delayed->cash branches retained. Other-fund overdueFIVE6 belongs CIO/retiredSocial; not resolved by Catalyst. Future size requires independently validated comparable costed edge, executable fresh quotes and exit before earliest news; calendar/fundamental updates alone change watch, not allocation.

Job24 lastOutput length2000 cut beforeTSM,HITI/BFRI; allfuturebranchesremaininjournalbutthecollectorwasnotdeliveringclaimedcoverage. Replacedwithacceptedjob30,720min64runs,then canceled24. Localtestpreserves2filingchecksand5source-linkedreminderswithENDmarker. Acceptedjob33,240min24runs,localtest1554bytes,collectsTLX/AVO/ABMRSS+UNFI8KfallbackandstaticSep8/9macro/reviewtimes. Initialnamevalidationrejectionretriedsuccessfully. AVOset_monitor422at20armed; no newarmedAVOmonitorclaimed. Firstsandboxoutputsnotyetavailable; nextSep7 00UTCrunmustverifyENDmarkersanderrorstates. Existing9/17/27active;9tailtruncatedbutleadingcurrentheadlinesareonlydiscovery,notcompleteprimarysurveillance. Thischangescollectionreliability,notinvestmentedge. Sources actuallist_jobsfundcatalyst+testedscriptoutputs;primaryfeedURLs https://telixpharma.com/feed/ ; https://investors.missionproduce.com/rss/news-releases.xml ; https://abm.gcs-web.com/rss/news-releases.xml ; SECfilings https://www.sec.gov/Archives/edgar/data/1020859/ . Noon/Sep9macroread-onlybranchesinanalysis432andnote405;goodnewdata->record/validate,adverse/nochange->cash. Noorderorstopautomation,allcashuntilindependentedge. Staticremindersarenotlivecalendarreverification. Limits latestitemonly,4hourcadence,missingIRfeedandunverifiedsavedfirstexecution areexplicit.

This is a calendar/execution audit of saved technical work, not fresh indicators or a new backtest. Previous Sep4 IEXanalysis50 CHWY close23.67,SMA20/50 23.35/22.25,ADR20 .88125,20daylow21.965; twoADR target25.4325 givesR/R(25.4325-23.67)/(23.67-21.965)=1.0337,below1.5. Currentmarketclosed; those are Friday references,notTuesdayquotes. Tighteningstopmerelytosatisfygeometrydoesnotvalidateinvalidation. Even2wholeshares47.34below49.14fundcash do notfixfailedT10holdout ormissingone-sessionedge. UNFI/ABMmorningSep8 release windowprecedesfirstregularsession; queuedwhole-shareovernightlimitscouldexposebeforefirstnewswithoutvalidatedentry/exit,thereforenone. AVOaftercloseSep8 allowsatmostsameregularsessionrun-up; mandatoryexitbeforefirstnewswouldbeSep8preclose withfreshproof,butnosuchvalidatedruleexists. Noholdingmeansnostops/targetsneedadjusting; theoreticallevelsareNOTorders. Gapbounded-riskclaimrejectedfromRARErealized-6.4403R. Source bars https://runway.adityaperswal.workers.dev/data/stock-bars ; https://investor.chewy.com/news-and-events/news/news-details/2026/Chewy-Announces-Fiscal-Second-Quarter-Financial-Results-Conference-Call/default.aspx ; https://abm.gcs-web.com/news-releases/news-release-details/abm-announce-third-quarter-2026-financial-results ; https://ir.unfi.com/events/default.aspx ; https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-release-fiscal-third-quarter-2026-financial . NoCLI rerun warranted totrustalreadyrejectedrule; a genericmomentumresultwouldnotanswerdatedone-sessionquestion.

Start49.14Catalystcash/account850.99,0open/queued; goal repeatable net pre-event gains. Bindingconstraint independently supported executableedge,not349.01monthlyshortfall. Premises1: NYSEholidaySep7 https://www.nyse.com/trade/hours-calendars leavesSep8/9nextsessions. 2: ConfirmedSep8morningUNFI/ABM;Sep8aftercloseBRZE/CASY/AVO;GMEcompleteSep8dateonlyandpreannounced. Sep9beforeopenCHWY/ASO;InditexSep9dateonly. FullissuerURLs/datesrecordedobservations7023–7031; newAVO https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-release-fiscal-third-quarter-2026-financial . UNFI/ABMhavezero remainingregularpre-releaseentrysessions;othershaveatmostoneUSsessionbeforefirstnews. 3: SavedCHWYfixed10sessionholdout-1.719988%,N6,p.5,W4.523%,L4.829%,quarterKelly0; shrinkingtoone-sessionrequiresnewvalidation. NewAVOCalavo acquisition makeshistoricalcomparabilityuncertain. 4: OfficialmacroSep8 10ETQFRmanufacturing/mining/wholesale/servicesandretail;15ETG19consumercredit;Sep9 10ETECEC/QSS. https://www.census.gov/economic-indicators/calendar-listview.html ; https://www.federalreserve.gov/newsevents/2026-september.htm ; https://www.bls.gov/schedule/2026/09_sched.htm . NFIBSep8inferredsecondTuesdaycadence,hournotverified. 5: NoSep8/9FDAdeadlineverifiedinboundedsearch;FDAhome https://www.fda.gov/advisory-committees displaysSep16/23upcomingpanels;TLXSep11goalretained https://telixpharma.com/news-views/fda-accepts-nda-for-tlx101-px-pixclara/ . Earlydecisionsremainpossible. Conclusion: zeroPROPOSE/EXIT/ADJUST/FUND;nostopsneededonflatbook,noqueuedholidaylimits. Validity: necessaryedge/windowgatesnotmet; soundnessboundedbypartialcalendarcoverage,censoredlivetrades,smallholdoutandunverifiedexecutiondata. Thisdoesnotpredictbadearningsoruniversalrunupfailure. Mindchanges: changedprimarydate/news->updatereview; positiveorganiccash->prospectiveindependenttest;actualriskonlyafterpositivecostedOOSuncertaintybound,comparablepipeline,firstnewsexit,R/R>=1.5andfractionalKellywithin49.14cash/account8.5099risk. Favorableheadlinesaloneinsufficient. Existing20armedCatalystmonitors,none due;AVOnewmonitorrejected20cap,usesjournalcollector;orphanFIVEbelongsretiredSocial/CIO,noCatalystaction. Jobs30replacestruncated24;newpreopenjobcollects3RSS+UNFISECandstaticmacrochecks. Noentryorautomaticexecutioneitherbranch.

Conditional chains, not forecasts. (1) Sep8consumercredit expansion/contraction changes evidence on household financing -> discretionary ASO and recurring CHWY demand expectations may diverge -> any price response must be distinguished from Sep9 company-specific earnings; credit growth alone is neither healthyconsumption norfinancialdistress. (2) Sep9 10ET employercompensationcost data may change labor-cost expectations -> labor-heavy ABM contract repricing/productivity economics may be reinterpreted after its Sep8 report -> margin/cash prospects can diverge from headline revenue; Juneperioddata is lagged, not live September payrollpressure. (3) AVO recovery in fruit-size supply andperunitmargin -> acquisition integration cash anddebtservice -> sustainable earningspernewshare; gross volume or nominal acquisitionrevenuealone doesnotcompletechain. Who benefits: distributors gain only if grossspread survives procurement/logisticscost; growersandretailersmay captureotherparts. (4) Favorable Pixclara decision -> label/reimbursement/manufacturingconstraints -> realized Telixcash; earlyadverseaction -> gap -> availablebookshrinks evenwithstop. Strongcounterargument: public calendar/currentguidance mayalreadypriceallofthis. Decisionchanges: newissuerinformation changescalendar/fundamentalwatch immediately; allocationchanges onlyafter independently preregistered costed holdout withpositiveuncertaintybound, comparable regime, fresh executablequotes andfeasibleR/R>=1.5. No assumed source-to-price causal coefficient or signed macrotrade. Sources https://www.federalreserve.gov/newsevents/2026-september.htm ; https://www.bls.gov/schedule/2026/09_sched.htm ; https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-second-quarter-financial ; https://telixpharma.com/news-views/fda-accepts-nda-for-tlx101-px-pixclara/ . Existing jobs/reviewscollect; no automaticorders.

AVO June8 Q2 primary release reports revenue290.9m,volume+15%,unitprices-36%,grossmargin7%,EBITDA7.1m vs19.1m. Higher unit demand did not create higher profit. Calavo closedMay28 afterApril30balance sheet:17.530823m shares issued,266m cash,combined88.3m shares/350mtermdebt. Q3EBITDA28–32m includes acquisition contribution, so beating last year's legacy business does not isolate organic improvement. H1cash33m is predeal; cannot subtract it from postdeal debt as contemporaneous netdebt. Q3guide midpoint30m versus7.1m Q2 is not a comparable organicgrowth rate. Bullcase volume,synergies and Q4Perufarming improvement may materialize; require organic unitmargin and integrationcash to substantiate. GME Aug31 preliminary operatingincome150–170m andnetincome290–310m include disclosed238mEBAYgain/75mdigitalassetloss; completeSep8 release adds less uncertainty than an unannounced quarter. Cannot subtract pretax marks mechanically from netincome withouttax bridge. TLX Aug20 retainsSep11Pixclara goal; Sep2BiPASS350-patient enrollment is prostate-imaging development, not glioma efficacy orapproval; Zircaix resubmission CRL is a third distinct exposure. Sources https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-second-quarter-financial ; https://investor.gamestop.com/news-releases/news-details/2026/GameStop-Announces-Second-Quarter-2026-Preliminary-Results/default.aspx ; https://telixpharma.com/news-views/telix-2026-half-year-results-strong-commercial-execution-and-momentum-in-late-stage-pipeline/ ; https://telixpharma.com/news-views/telix-completes-enrollment-in-phase-3-bipass-study-aligns-with-fda-on-nda-pathway/ . Facts support prospective review, not price targets orpositive edge. No current valuation or consensus-surprise modelestablished; sizezero.

Recomputed all3Catalyst trades with numpy from query_trades,Sep2–4 execution record. Equal-trade mean-16.3806%,wins0/3,totalPNL-31.937258 matches venue-31.94 rounding. Two operator exits censor intended strategy outcomes; one RARE stop exit-45.8601% realized-6.44035R. No winners means averagewin unavailable; do not fabricate W or infer a precise future p=0 from3selectedtrades. Live record therefore cannot calibrate positive Kelly. Saved independent CHWY event holdout analysis38 (recovered via analyses64/172) N6,p=.5,W4.523%,L4.829%,netreturn-1.719988%; clipped quarterKelly max(0,(p-(1-p)/(W/L))/4)=0. Its ten-session rule is not a validated Sep8 one-session substitute. RARE historical-loss stress on49.14cash=22.5356USD exceeds8.5099account risk cap; no claim this observed loss bounds futuregaps. Premises: failed/unknownedge+unvalidatedwindow imply no size; counterexample a future rally would not refute missing ex-ante edge. Source execution ledger query_trades fund=catalyst; historicalbars https://runway.adityaperswal.workers.dev/data/stock-bars ; dates https://investor.chewy.com/news-and-events/news/news-details/2026/Chewy-Announces-Fiscal-Second-Quarter-Financial-Results-Conference-Call/default.aspx . No new backtest or MonteCarlo claimed; resampling3censoredtrades would not create evidence.

Start: Catalyst49.14cash,account850.99,noopen/queuedorders. Goal: net repeatable gains with exit before documented events. Bindingconstraint: independently supported executable edge,not whole-share affordability. Premises1 issuerAug17 confirmsSep14before-open results; historicalissuerdate/noticepairs allowpoint-in-time study. 2 fixedT10 training+39.39% becomesholdout-54.90%,N6,win16.67%,W19.9738/L17.1668%; quarterKelly max(0,(p-(1-p)/(W/L))/4)=0. 3 recentpriceuptrend/currenthighvol has0trainingcases;5sessionrulealsofails;15session has0training and1positiveholdout,not validation. 4 IEXdailyMC is conditional onsixobservedwindows;mean-5.847%,cannotbound unseenjumps. 5 twoADR/low20 R/R.508 fails1.5 evenbeforeexecutioncosts. Conclusion: no PROPOSE,EXIT,ADJUST orFUND; keep49.14cash. Validity:failed/unknownedge entailszero size undermandate;doesnotentailnegativefutureearnings. Soundness: computationscrosscheckedvectorbt/directcompounding,primarydatepairsrecorded; omittedsurprisepreannouncements/actionmapping andpartialIEXfills constrain claims. Strongbullcase: current20sessiongain26.13%,cashimprovement,andSep2025annualrunup+19.97%; oneannualwinner andturnaroundstory cannotoverturn independentnetfailures. Priorwillingtobuy wouldchange onlyafterfreshprospective comparableeventevidence yieldspositive netmean lowerconfidencebound andfeasibleR/R,not afterparameterfitting. Existingmonitor39Sep14 12:30UTC researchonly; goodcash/volume/margin->recordfornewstudy,weakness->retainrejection,neitherautomaticentry. No dueCatalystmonitoror neededactionbefore08UTC. Sources https://ir.hain.com/news-releases/news-release-details/hain-celestial-announces-fiscal-2026-fourth-quarter-and-full ; https://ir.hain.com/financial-information/quarterly-results ; https://runway.adityaperswal.workers.dev/data/stock-bars . Analyses346,356,358,382–385,392–393;72partarchivecomplete.

Executed actual command node /app/agent/dist/backtest.js --symbols HAIN --strategy momentum --lookback 20 --days 2000 with venue livefetch.1376bars,58trades,return-84.243267%,DD87.561226%,win25.862069%,average-3.255212%,buyhold-98.314055%. CLI has no independent costed train/holdout split and crosses earnings; do not use its figures as event-rule edge or allow relativeoutperformance versus collapsingbuyhold to imply profit. The separatelyrecorded vectorbt event study382 provides preregistered chronological costed holdout. Source https://runway.adityaperswal.workers.dev/data/stock-bars ; exactoutput and scripts archived.

Numpy seed60606. Resample50000 whole10-session OHLCwindows from13training events, separately50000from6holdout events; normalize each entryopen to1. Fixed currentSep4 barriers -ATR14/close=-9.93029% and+2ADR20/close=+16.25249%; these contemporary barriers are diagnostic,not an out-of-sample historical rule. Openinggaps execute first atopen; otherwise samebarbothhit usesstopfirst; timeexitT-1close. Fee5bp/slip10bp eachside. Trainingmean+3.318961%,win61.48%,target7.866%,stop0%,time92.134%;holdoutmean-5.847043%,win16.676%,target16.676%,stop83.324%,time0%,meanexit5.1824sessions,p05-10.200095%. Only6independent holdoutwindows;50000draws donot increase evidence. Modeledriskbreach>8.5099USD at49.14notional=0%,becauseempiricalsampleanddailybarfillassumptions omit unseenjumps/15minexecution; NOT a safetybound. No measuredprobability of surpriseannouncement. Separate12-trade iid compounding simulation50000paths resamples6baselineholdoutreturns with rebalancedfundfractions0/.25/.5/1: medianending49.14/34.69212/23.70674/9.94125USD,p05=49.14/27.60792/14.86756/3.66715;lossprob0/98.78/99.042/99.354%. Twelvequarters is a multiyear scenario,not thismonth forecast. Invariant assumeddistribution,no taxes/recurringoverhead; fees already intrade returns. QuarterKelly0 fromobservededge overrides all hypotheticalallocations. Source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=HAIN,SPY,XLP&timeframe=1Day&feed=iex&adjustment=all .

Sep4 IEXclose.7521,SMA20 .68332,SMA50 .605924,20sessionreturn26.12779%,annualized20dayclosevol140.95628%. ADR20 .061115,ATR14 .074685714;20daylow.5116/high.9048;meanIEXvolume18547.95 partialmarket,not totalADV. TwoADR target.87433 versuslow20stop.5116 givesR/R.50823,below1.5. ATRstop.6774143 would be a diagnosticrangebarrier,not demonstratedthesisinvalidation. At65whole shares cost48.8865 beforefees, low20risk15.6325>account1%8.5099;max35shares from that stopdistance alone,stillrejectedonedge. Worsthistoricalovernightgap-30.43478%,not upperlossbound;65sharelossatthatgap~14.88USD. Close canchangebeforeTuesday; no queuedlimit or currentquote claim. Fractionals unnecessary for affordabilitybutnofillliquidityverified. No holdingRprogress toreview. Source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=HAIN,SPY,XLP&timeframe=1Day&feed=iex&adjustment=all ; venuecontextbook49.14/account850.99.

Indicators use only priorclose at entry. Trend=close>SMA20>SMA50; highvol=ATR14/close above training-onlymedian3.0091043%. Training: trendfalse/lowvolN6 mean-.23825%,trendfalse/highvolN6 +5.82893%,trendtrue/lowvolN1 +1.85433%,trendtrue/highvolN0. Holdout all6highvol; trendfalseN3 mean-18.01258%,win0%;trendtrueN3 mean-3.94076%,win33.3333%. Thus currenttrendtrue/highvol regime has no training support; do not fit interactions or infer probabilities from emptycells. ATR/returncorr+.718389train versus-.034644holdout is descriptive and tiny-sample. SPYaboveSMA50 holdoutN5 mean-11.04040%,belowN1-10.65804%; broaderuptrend doesnotrescue. Correlated price indicators are not independent confirmations. Knownpreannounced2022windowN1+6.55701% excluded from cleantraining leavesN12+30.80863%,but currentfuturepreannouncementstatus not exhaustively proven. These diagnostics inspect holdout and cannot become newly validated filters. Source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=HAIN,SPY,XLP&timeframe=1Day&feed=iex&adjustment=all .

FixedT10 holdoutN6 mean-10.97667%;50000iid event bootstrap seed60606 95%meanCI[-23.21708,2.91121]%;onewinner Wilson95%winCI[3.00534,56.35028]%. Unknown serial/regime dependence and small sample mean CI is conditional,not precise forecast. Training-minus-holdout mean difference bootstrap seed60607 CI[-.72947,26.15507]points: descriptive deterioration does not prove a statistically identified break. Mean netHAIN minus grossSPY samewindow-12.39050points,minusgrossXLP-11.19342; controls cost-free intentionally favorcontrol and are not a hedgedportfolio. 420dailyreturns2025–Sep4 2026: OLS intercept-.4030566%/day,betaSPY.7719663,betaXLP.9985779,R2.05130145; correlationsHAIN/SPY.1668041,HAIN/XLP.1814433. No robustSE,causalalpha,or stationarity assumed. Single surviving issuer selected by existingdatedwatch,not representative marketcohort; repeatedfundresearch creates selection risk across names. Need prospective independent post-restructuring sample,not more bootstraps of same6. Source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=HAIN,SPY,XLP&timeframe=1Day&feed=iex&adjustment=all ; issuer-date sources in22observations.

Preregistered note353 before prices inspected. Issuer archive recovered22 actual release dates2021–May2026 plus prior scheduling notices, each recorded withURL. Require notice published on earlier calendar day than entry; call-only notice matched actual release date, no assumed first-news minute. EnterT-10open,exitT-1close onSPYsessioncalendar,nevereventday. Three training events excluded for same-day notice (Feb9 2021,Nov8 2022,Aug24 2023); zero missing-bar exclusions. Training2021–2024N13 +39.38577%,DD14.29358%,win61.53846%; holdout2025–May2026N6 -54.89695%,DD56.61701%,win16.66667%,mean-10.97667%,W19.97380/L17.16676%. vectorbt open/close two-observation sessions, all-in notional reinvestment; fee5bp/slip10bp eachside; independently matches direct trade compounding. DD measured at opens/closes,not true intradayworst. Higher25bpslip holdout-55.70154%. $0.005/$0.01slip per side separately -56.12889/-57.83791%. Fixed5session diagnostic holdout-20.19879%N6;15session has0training/1holdout +23.41144%,unusable calendar selection. No strategy selection from inspected sweep. One2022preannouncement tagged,not fresh economicnews. CurrentT10entry alreadypassed; cannot turn late entry into testedrule. Source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=HAIN,SPY,XLP&timeframe=1Day&feed=iex&adjustment=all ; https://ir.hain.com/financial-information/quarterly-results . IEXpartialvenue and hypotheticalcosts do not establish executablefills; corporate-action mapping and all unscheduled preannouncements not exhaustively audited. Reject longrule,not shortrecommendation.

Read query_trades fund=catalyst Sep6. Three closed trades, wins0; returns MIRM-.439321%,IONS-2.842420%,RARE-45.860062%; arithmetic average loss16.380601%, dollarPnL-31.937258 before unallocated system costs. Two operator liquidations confound intended-horizon outcome; one recordedstop sale. RARE exit13.98976 versusstop24 is41.709333% below trigger, not necessarily order-routing slippage: no contemporaneous executable quote captured. All were fractional market-notional entries; no limit comparator and no reference quote to estimate entry slippage. Winnerpayoff unobserved, quarterKelly sizing0 by mandate. Do not pool these three FDA names as an earnings event sample or infer a stable0% true win probability. Source runway:query_trades?fund=catalyst&status=closed ; venue/context providesaccount850.99,fund49.14,1%risk8.5099. This is execution/outcome evidence, not a causal rule backtest.

Premises from May11 Q3 issuer: divestiture changes portfolio; organic volume/mix falls11points, pricing offsets5; CFO38m and netdebt505m. 1st order: fewer low-margin operations and debt paydown can improve cash burden while reducing reported sales. 2nd: remaining operations must absorb stranded costs; pricing can protect margin but further weaken price-sensitive demand, so cash and organic volume need separate tracking. 3rd: sustained cash generation could improve refinancing terms and equity residual value; persistent volume weakness could leave creditors with most benefit and equity exposed to restructuring costs. These are conditional mechanisms, not measured peer earnings impacts. Beneficiaries: creditors from deleveraging, buyers of divested brands from acquired operations; shareholders only if retained cash earnings improve. Strong contrary case: brand resilience and cost removal outweigh volume declines. Counterargument does not establish short-window price alpha. Source https://ir.hain.com/news-releases/news-release-details/hain-celestial-reports-fiscal-third-quarter-2026-financial . Existingmonitor39 compares cash/debt/volume either way; no order.

Premises: May11 issuer Q3 endedMar31 reports organic sales-6% from volume/mix-11points and pricing+5, adjustedEBITDA26m versus34m, CFO38m andFCF35m; debt549m/net505m. These are issuer-selected adjusted metrics, not independent endorsement. Inference: debt reduction can aid equity while underlying demand remains weak; divestitures change comparability. Strong bull counterexample is margin/cash improvement despite shrinking volume; bear counterexample is working-capital release that cannot repeat. Need September14 complete results before assuming sustained cash conversion. No valuation target derived from one quarter or annualized seasonalFCF. Primary source https://ir.hain.com/news-releases/news-release-details/hain-celestial-reports-fiscal-third-quarter-2026-financial .

Start:fund49.14cash,account850.99,noopen/queuedlots. Goal:repeatable net gains exiting before dated news. Binding constraint:independent executable edge, not a compelling approval story. Premises1 issuerAug21 confirmsSep30deadline but allows earlierapproval; Sep9/10conferences precedeit.2 DirectFDA/EMA evidence supports a manufacturing constraint, not certain failure of unnamedreplacement; chronologicalchangesandtrial/date discrepancies preserved.3 Event302 loses5.45% onsolecompletedwindow; noeventholdout. Momentum303 loses36.34%,N25,36%wins,W5.3818/L5.4618%,rawKelly-.2895->quarterKelly0.4 Technical310 cannotfitwhole55.305sharewithin49.14book; low20/twoADRgeometryR/R.8325.5 Simulation330assumedhazard cannotbeusedasestimatedwinprobability. ConclusionnoPROPOSE/EXIT/ADJUST/FUND. Validity:unknown/failednetedge meanszeroauthorizedsize; itdoesnotpredictCRLornegativeprice. Soundness:primarytiming/finances andbarcalculationsverified; limitedeventhistory,partialIEX,unknownreplacementstatus anddailyexecutionmodel limitinference. Strongbullcaseisalternateapprovalunlockinglaunch/150mdebt; thatfactalonecannotrepairtradepayoff. Favorablefutureevidence->recordandindependentlyvalidate;adverse/noevidence->cash. Monitors20full,existing24Sep29retained,Sep9requestrejected; compactjob27every480min90runs carries earlierreminders,notexecution. Job26cancelledafterconfirmedtruncatedoutput. Archive81parts/note332; correctedcollector337. No actionduebefore06UTC. Sources https://scholarrock.gcs-web.com/news-releases/news-release-details/scholar-rock-provides-update-global-apitegromab-regulatory ; https://download.open.fda.gov/crl/CRL_BLA761463_20250922.pdf ; https://runway.adityaperswal.workers.dev/data/stock-bars .

100000numpy paths,seed60604,10sessions; sample two5-day blocks from latest252dailySRRKclose returns including tails. Diagnostic exits at first sampled close crossing +2ADR(+6.8113%) or -1ATR(-3.6738%), otherwiseday10; fees5/slip10bp eachside. This approximates neither continuous fills nor15minutevenue execution. Inject independent-30%adversejump atuniformday with assumedwindowprobability0/1/5/10%; it matters onlybeforemodeledexit. NoeventhazardestimatedfromN1, noapprovaljumpmodel, existinghistoricaltailscanoverlapinjectedstress. Means1.4974/1.3593/.7600/.0374%,win47.536/47.288/46.265/45.027%;5thpercentiles-7.4857/-7.5778/-9.5225/-14.2296%. At10%assumedhazard,4.603%paths lose>$8.5099whenhypotheticallydeployingfull49.14. Evenzero-addedhazardhasovershoot becausechecksareatdailyclose. These are conditional stress outputs, notforecastwinprobabilitiesorapprovedsizing. A30%jumpalone on49.14loses14.742USD>account1%8.5099; atmost28.3663USDwouldmeetthatparticularjump-onlybudget,notaguaranteeagainstworsejumps. Full-losscap8.5099alsofailswhole-shareaffordability. Empiricalmomentumedge303negative;quarterKelly0overridespositivebootstrappedpathmean. Source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SRRK&timeframe=1Day&feed=iex&adjustment=all . Facts end atbarreturns; allhazard/jumpparametersareexplicitassumptions.

Sep4IEXclose55.305 belowSMA20 55.6155,aboveSMA50 53.4402,20sessionreturn4.4772%; correlatedpriceindicatorsnotindependentconfirmations. ADR20 1.8835,ATR14simplemeanTR2.03179,20daylow50.78/high61.75,20dayannualizedclosevol36.0533%,IEXmeanvolume68740.65partialmarket. TwoADRtarget59.072 versus low20stop50.78 yieldsR/R.8325,below1.5. Tighter oneATRstop53.2732 would be a modeledrangeexit,notdemonstratedthesisinvalidation; notadopted. Fund49.14 cannotbuywhole55.305share,12.5458%shortbeforefees; fractionscannotexitextendedhoursunderprovidedvenue rules. FixedT20currententrySep1passed. HistoricalworstIEXovernightgap-16.5104%Oct13 2025; Sep23CRLannouncementopen29.91vs32.63priorclose=-8.3359%,dayclose33.77=+3.4937%: close-onlyoutcomemasksintradaygaprisk. Theseareobservedfeedprices,notcausalCRLreturnestimates. Noactiveholdings,Rprogressorexitadjustments. Source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SRRK&timeframe=1Day&feed=iex&adjustment=all ; fundbook/venuerulesfromSep6runcontext. Conclusionzeroentry on failededge,geometryandexecution constraints.

Premises: same stock onlyonecompletedFDAdeadline; arbitrary stock windows measure backgrounddrift,notdatededge. Fixed15sessionnonoverlapping windows with16sessionstep,IEX2021–Sep42026,fee5/slip10bp eachside. Train61windows mean1.2841%,median-1.5474%,win45.9016%,bootstrap95%meanCI[-6.0859,11.4398]%. Holdout25windows fullyentered/exited2025+,mean1.6538%,median.8703%,win56%,CI[-3.6993,7.1608]%; oneDec18–Jan13boundarywindowexcluded explicitly. 20000iidbootstrapresamples,seed60604; nonoverlapreducesmechanicaldependencebutregimeautocorrelationremains. Descriptive420dailyrows2025+:corrSRRK/XBI.5691,SPY.3380;twofactorOLSbetaXBI1.2164,SPY.09075,dailyintercept-.06767%,R2.3243. No robustSEorcausalclaim; XBIcontainsbiotechexposureandfactorscorrelated. Conclusion: risingpriceorpositiveplacebomeandoesnotidentifyeventpremium. Need prospective independentlyclassifiedmanufacturing-resubmissioncohort with announcements knownbeforeentry and fullpipelineoverlap. No posteriorapprovalprobability assigned; N1cannotcalibratehazard. Source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SRRK,XBI,SPY&timeframe=1Day&feed=iex&adjustment=all . Allmeasuredrows/metrics archived.

Ran actual CLI node /app/agent/dist/backtest.js --symbols SRRK --strategy momentum --lookback20 --days2000, live venuefetch succeeded. CLI1376bars,72trades,return-50.2208%,DD71.2093%,win26.3889%; no costed independent holdout inCLI itself. Separate vectorbt test: daily prior-close sign of5/10/20session return executed nextIEXopen; fixed through2024 training,2025-Jan–2026-Sep4holdout; lastopen liquidation,no optimizedstops. Baseline20 training-67.6483%,N52; holdout-36.3390%,DD42.5445%,N25,win36%,avgW5.3818%,avgL5.4618%. Fee5bp+slip10bp per side. Stress5+25bp:holdout-40.9389%. Heldout5day-45.3578%,10day-9.47835%; allcostedreturnsnegative. Sweep is robustness diagnostic, notselection. Entry/exitpricesIEXpartialvenue;dailyopenfillsnotactualquotes,no15minutevenueexecutionreplication. Positive arithmeticmean for10day atbasecostdoesnotrepairnegativecompoundedreturnortrainingfailure. BaselinequarterKelly=max(0,(.36-.64/(5.3818/5.4618))/4)=0. This rule is not a PDUFA run-up and cannot validate one. Source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SRRK&timeframe=1Day&feed=iex&adjustment=all ; exactCLIjson,12sweeptradeCSVs andscriptretained.

Preregistered note293 fixed T-20 close to T-5 close before issuer PDUFA. Aug6 2025 issuer notice establishesSep22 deadline before entry. IEX all-adjusted bars2021-Jan4–2026-Sep4,1425sessions; source https://runway.adityaperswal.workers.dev/data/stock-bars?symbols=SRRK&timeframe=1Day&feed=iex&adjustment=all . Vectorbt fee5bp/slippage10bp each side, cash100: Aug22close35.495 ->Sep15close33.66,return-5.453807%, marked-to-closeDD12.119469%,N1,win0%; sole loss5.453807% of invested cash, average win undefined. Trade-record denominator differs slightly:-5.456534%. XBI same-window gross+2.706883%. Stress30bp total each side approximately-5.73702%. OriginalCRL signedSep22,publicSep23; this window actually exited beforedecision, yetlost. One completed original submission is not a matched resubmission corpus; chronological event holdoutN0 because2026pending. Current rule would enterSep1 andexitSep23 (weekdaycalendarexcludingLaborDay); entryalreadygone, no catch-up variation authorized. Validity: reject deployment because evidence lacks independent positive expectancy, not becauseN1provesallPDUFArunupsfail. No event early-hazard frequency inferred. Sources https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-reports-second-quarter-2025-financial-results-and ; https://download.open.fda.gov/crl/CRL_BLA761463_20250922.pdf . Price/source rows and scripts archived in this run.

Premises from recorded FDA/EMA/sponsor sources: original plant removed; alternate review pending; SMA trial adds treatment to existing SMN therapies; financing partly conditional on approval. First order favorable approval can unlock commercial shipments and optional150m borrowing; adverse review postpones both. Second order launch consumes working capital, supports compliant fill-finish suppliers and adds payer cost alongside existing SMN therapies; approval does not imply replacing nusinersen/risdiplam revenue. Third order net reimbursement, sustained functional benefit and access determine whether revenue covers launch costs and financing claims; repeated delay can force further equity funding. These are causal scenarios, not company-specific earnings forecasts or approval probabilities. Novo owns the original plant, but customer relationship is not evidence of an acquisition or alternate-site compliance. Beneficiaries include patients if useful access expands, lenders receiving interest and compliant suppliers; management benefits from launch optionality. Strong counterargument: removing an already identified CMC obstacle with supply ready could trigger repricing beforeSept30. That possibility supports monitoring, not a calibrated trade. Clinical evidence is156 main plus32 exploratory; do not treat EMAs188 age-summary as a second efficacy sample. Sources https://www.ema.europa.eu/en/medicines/human/EPAR/isembyld ; https://investors.scholarrock.com/static-files/e4533b5a-14df-4515-bf7b-75b503a36b0d ; https://www.sec.gov/Archives/edgar/data/1727196/000119312526336732/srrk-20260630.htm ; https://scholarrock.gcs-web.com/news-releases/news-release-details/scholar-rock-announces-fda-review-apitegromab-biologics-license . No separate fund: no measured supplier or companion-drug stock edge.